ATS (ATS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
30 Jun, 2026Executive summary
Fourth quarter bookings reached CAD 863 million, up 9% year-over-year, with diversified growth across all markets and strong contributions from acquisitions.
Full-year bookings hit a record CAD 3.3 billion, up 14.3% year-over-year, setting a strong foundation for fiscal 2026.
The company settled a major EV customer dispute, resulting in a one-time after-tax impact of CAD 129 million and a $171.1 million pre-tax charge, but improving financial flexibility and leverage.
Recent acquisitions of Paxium and Heidolph expanded the product portfolio and contributed to growth in life sciences and food & beverage.
Strategic focus remains on innovation, operational efficiency, and disciplined M&A to drive long-term shareholder value.
Financial highlights
Q4 adjusted revenues were CAD 721 million, down 9% year-over-year due to lower EV revenues; full-year adjusted revenues declined 12%.
Q4 adjusted earnings from operations were CAD 74 million, down 23% from the prior year, mainly from lower transportation volumes.
Q4 adjusted EBITDA was $97.1 million (down 16.1% year-over-year); Q4 net loss was $(68.9) million.
Adjusted EPS for Q4 was $0.41, down from last year; full-year adjusted EPS was $1.47, down from $2.61.
Free cash flow for fiscal 2025 was negative $52.3 million, compared to negative $67.6 million last year.
Outlook and guidance
Order backlog ended the quarter at approximately CAD 2.1 billion, the highest in eight quarters, supporting revenue visibility for fiscal 2026.
Q1 fiscal 2026 revenues are expected in the range of CAD 680 million–CAD 730 million.
Management expects margin expansion in fiscal 2026 as life sciences bookings convert to revenue and transportation volumes recover.
Effective tax rate is expected in the mid-20% range going forward.
Margin expansion initiatives are ongoing, but inflation and supply chain volatility may impact short-term results.
Latest events from ATS
- C$3.0B adjusted revenue, strong M&A, and disciplined growth in automation markets.ATS
Investor presentation29 May 2026 - Revenue and earnings rose in fiscal 2026, with restructuring driving margin expansion.ATS
Q4 202628 May 2026 - Record financial results, all resolutions passed, and strategic focus on regulated markets.ATS
AGM 202419 May 2026 - Flexible shelf offering supports growth in automation for regulated, high-value markets.ATS
Registration filing27 Apr 2026 - C$2.9B adjusted revenues, 13.8% EBITDA margin, and robust M&A fuel global automation growth.ATS
Investor presentation19 Apr 2026 - Margin expansion, portfolio diversification, and disciplined M&A drive future growth plans.ATS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q3 revenue up 16.7%, net income surges, and strong backlog supports future growth.ATS
Q3 20264 Feb 2026 - Life sciences and nuclear energy drive growth, with disciplined M&A and resilient market focus.ATS
Raymond James 46th Annual Institutional Investors Conference3 Feb 2026 - Order bookings surged 18.4% as life sciences growth offset transportation softness.ATS
Q1 20252 Feb 2026